Medtide

Medtide P/B

The P/B (Price-to-Book Ratio) of Medtide (3880.HK) as of Oct 22, 2026 is 2.08. In the previous year, P/B (Price-to-Book Ratio) was 10.34 — a change of -79.89% (lower).

P/B

2.08

YoY

-79.89%

Last updated:

P/B (Price-to-Book Ratio) of Medtide is 2025 2.08 . P/B (Price-to-Book Ratio) of Medtide was 2024 10.34 . It decreases by -79.89% lower compared to the previous year.

The Medtide P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2021
31.36 CNY
Jan 1, 2022
16.28 CNY
Jan 1, 2023
12.99 CNY
Jan 1, 2024
10.34 CNY
Jan 1, 2025
2.08 CNY
The Medtide P/B history
YEARP/BYoY
2.08-79.89%
10.34-20.35%
12.99-20.25%
16.28-48.07%
31.36—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medtide Stock analysis

What does Medtide do? Medtide, Inc. generates revenue through peptide-focused contract research, development, and manufacturing services. The company offers CRO services for peptide new chemical entity (NCE) discovery and synthesis, alongside CDMO services covering peptide chemistry, manufacturing, and control (CMC) development and commercial production. Its primary clients are pharmaceutical companies seeking active pharmaceutical ingredients (APIs) rather than finished drug products, with services delivered across domestic and overseas markets. The firm's revenue streams are derived from these specialized peptide-related R&D and manufacturing contracts. Medtide's business model centers on providing comprehensive peptide development and manufacturing solutions, including CMC filing support for clients. The company's services target the API segment of the pharmaceutical industry, focusing on peptide-based drug development rather than final drug formulations. This specialization allows Medtide to serve clients requiring high-quality peptide synthesis and manufacturing capabilities for their drug development pipelines. The company's revenue is generated through direct contracts with pharmaceutical firms for peptide-related services, including discovery synthesis, CMC development, and commercial manufacturing. These services are delivered to clients operating in both domestic and international markets, with the firm emphasizing its expertise in peptide chemistry and manufacturing processes. Medtide's business model relies on its ability to provide end-to-end peptide development and manufacturing solutions to pharmaceutical clients. Medtide is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medtide stock

P/B (Price-to-Book Ratio) of Medtide is 2.08 in 2025.

P/B (Price-to-Book Ratio) of Medtide changed from 10.34 to 2.08, representing a -79.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Medtide since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Medtide with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Medtide

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Medtide